Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -178.06% is in line with its 5-year average of -178.51%, around the middle of its 5-year range (-503.05%–-20.43%).
As of the fiscal period ended Tuesday, June 30, 2026. 29.87% above its 12-month average of -253.90%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -178.06%.
RETURN ON EQUITY (ROE)
-178.06%
RETURN ON EQUITY (ROE) AVG TTM
-253.90%
RETURN ON EQUITY (ROE) AVG 3Y
-229.45%
RETURN ON EQUITY (ROE) AVG 5Y
-178.51%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+29.87%
CURRENT VS 3Y AVG
+22.40%
CURRENT VS 5Y AVG
+0.26%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-323.84%
vs the sector median at left
Gain Therapeutics, Inc.
Market Cap
$71.23M
Return on Equity (ROE)
-178.06%
TTM Avg
-253.90%
3Y Avg
-229.45%
5Y Avg
-178.51%
Market Cap
$70.63M
Return on Equity (ROE)
-35444.23%
TTM Avg
-17872.82%
3Y Avg
-9061.56%
5Y Avg
-6066.76%
Market Cap
$72.32M
Return on Equity (ROE)
-724.01%
TTM Avg
352.19%
3Y Avg
76.05%
5Y Avg
9.78%
Market Cap
$72.83M
Return on Equity (ROE)
-250.39%
TTM Avg
-122.53%
3Y Avg
-92.00%
5Y Avg
-67.18%
Market Cap
$69.61M
Return on Equity (ROE)
-29.15%
TTM Avg
47.40%
3Y Avg
90.52%
5Y Avg
62.16%
Market Cap
$73.27M
Return on Equity (ROE)
-94.81%
TTM Avg
-84.90%
3Y Avg
-70.34%
5Y Avg
-58.48%
Market Cap
$68.90M
Return on Equity (ROE)
16.70%
TTM Avg
-67.07%
3Y Avg
-43.48%
5Y Avg
-55.81%
Market Cap
$68.10M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
Market Cap
$67.52M
Return on Equity (ROE)
-38.55%
TTM Avg
-81.03%
3Y Avg
-175.38%
5Y Avg
-133.71%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $71.23M | -178.06% | -253.90% | -229.45% | -178.51% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | -35444.23% | -17872.82% | -9061.56% | -6066.76% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | -724.01% | 352.19% | 76.05% | 9.78% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | -250.39% | -122.53% | -92.00% | -67.18% |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | -29.15% | 47.40% | 90.52% | 62.16% |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | -94.81% | -84.90% | -70.34% | -58.48% |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 16.70% | -67.07% | -43.48% | -55.81% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 68.12% | -94.32% | -166.28% | -128.51% |
| iBio, Inc. (IBIO)vs › | $67.52M | -38.55% | -81.03% | -175.38% | -133.71% |
| Pulmonx Corporation (LUNG)vs › | $75.18M | -122.76% | -82.75% | -63.80% | -49.10% |
ROE
-178.1%
ROA
-130.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -178.06% |
| 2026-03-31 | -151.64% |
| 2025-12-31 | -108.60% |
| 2025-09-30 | -328.15% |
| 2025-06-30 | -503.05% |
| 2025-03-31 | -362.08% |
| 2024-12-31 | -278.10% |
| 2024-09-30 | -239.83% |
| 2024-06-30 | -183.28% |
| 2024-03-31 | -244.67% |
| 2023-12-31 | -177.03% |
| 2023-09-30 | -303.08% |
| 2023-06-30 | -198.85% |
| 2023-03-31 | -128.51% |
| 2022-12-31 | -93.17% |
| 2022-09-30 | -71.20% |
| 2022-06-30 | -60.12% |
| 2022-03-31 | -46.23% |
| 2021-12-31 | -39.90% |
| 2021-09-30 | -32.83% |
| 2021-06-30 | -20.43% |
| 2021-03-31 | -12.24% |
| 2020-12-31 | -57.69% |
| 2020-09-30 | -33.62% |
